Contribution: Industrial Research Assistance Program – Contributions to Firms
Jenthera Therapeutics inc.
$98,270.00
In vivo proof of concept study of Nuc-Nab gene editing complex targeting the KRAS oncogene
FY 2021-22 · 2021-12-20
Summary
Using a known oncogene as the target, this project will aim at generating a proof of concept in animal for a novel gene editing therapeutic platform. Using a proprietary targeting mechanism, prior to the proposed project, in vitro demonstrations with very encouraging results were obtained.
Department
Program
Industrial Research Assistance Program – Contributions to FirmsIndustrial Research Assistance Program-Contributions to Firms (linked with high confidence)
Recipient
Location
Montreal|Montréal, Quebec, Canada
Recipient Type
For-profit organization
Business Number
701783482
Type
Contribution
Source
Proactive Disclosure - Grants and Contributions
Amendments
Each version of the agreement as published, oldest first, with its total as of that version. The amount above is the latest.
| Amendment | Date | Fiscal Year | Total |
|---|---|---|---|
| 0 | 2021-12-20 | 2021-22 | $98,270.00 |
| 2 | 2021-12-20 | 2021-22 | $98,270.00 |
| 4 | 2021-12-20 | 2021-22 | $98,270.00 |
As published
Additional Information
This agreement has been amended 2 time(s). The end date of this agreements has been modified by 70 days.
Additional Information (French)
Cet accord a été modifié 2 fois La date de fin du présent accord a été changé de 70 jours.
Agreement End Date
2022-12-30
Agreement Number
983780
Agreement Start Date
2021-12-20
Agreement Title
In vivo proof of concept study of Nuc-Nab gene editing complex targeting the KRAS oncogene
Agreement Title (French)
Étude de preuve de concept in vivo du complexe d'édition de gènes Nuc-Nab ciblant l'oncogène KRAS
Agreement Type
Contribution
Agreement Value
$98,270.00
Amendment Date
2022-09-01
Amendment Number
4
Coverage
IRAP Contributions to Firms projects stimulate wealth creation for Canada through technological innovation. | Les projets des Contributions aux entreprises stimulent la création de richesse au Canada grâce à l’innovation technologique.
Description
Using a known oncogene as the target, this project will aim at generating a proof of concept in animal for a novel gene editing therapeutic platform. Using a proprietary targeting mechanism, prior to the proposed project, in vitro demonstrations with very encouraging results were obtained.
Description (French)
En utilisant un oncogène connu comme cible, ce projet visera à générer une preuve de concept chez l'animal pour une nouvelle plateforme thérapeutique d'édition de gènes. En utilisant un mécanisme de ciblage propriétaire, des démonstrations in vitro avec des résultats très encourageants ont été obtenues avant le projet proposé.
Expected Results
The purpose of IRAP Contributions to Firms is to support research, development, adoption and/or adaptation of innovative or technology-driven new or improved products, services or processes in Canada up to their commercialization
Expected Results (French)
Le PARI, par le biais des Contributions aux entreprises, vise à appuyer la recherche, le développement, l’adaptation et/ou l’adoption au Canada de produits, de services ou de processus novateurs ou axés sur des technologies nouvelles ou améliorées, et ce jusqu’à leur commercialisation
Federal Riding
Mount Royal
Federal Riding (French)
Mont-Royal
Federal Riding Number
24052
NAICS Code
339110
Organization Code
nrc-cnrc
Organization
National Research Council Canada | Conseil national de recherches Canada
Program Name
Industrial Research Assistance Program – Contributions to Firms
Program Name (French)
Programme d’aide à la recherche industrielle – Contributions aux entreprises
Program Purpose
The purpose of IRAP Contributions to Firms is to support research, development, adoption and/or adaptation of innovative or technology-driven new or improved products, services or processes in Canada up to their commercialization
Program Purpose (French)
Le PARI, par le biais des Contributions aux entreprises, vise à appuyer la recherche, le développement, l’adaptation et/ou l’adoption au Canada de produits, de services ou de processus novateurs ou axés sur des technologies nouvelles ou améliorées, et ce jusqu’à leur commercialisation
Recipient Business Number
701783482
Recipient City
Montreal|Montréal
Recipient Country
CA
Recipient Legal Name
Jenthera Therapeutics inc.
Recipient Postal Code
H4W 1K7
Recipient Province or Territory
QC
Recipient Type
F
Reference Number
172-2021-2022-Q3-983780
